CS Paper Radar

Artificial intelligence surrogates for treatment effect estimation with before-and-after data

Frances Dean, Anna Neufeld, Joshua Barrios, Geoffrey H Tison, Ahmed Alaa

cs.LG stat.ML ·submitted 2026-09-23 00:34 UTC · v1

Abstract

Estimating the causal effects of medical treatments is difficult when clinically important outcomes are costly to measure or require long follow-up. Short-term or inexpensive surrogate outcomes offer a potential alternative, but surrogate biomarkers may be unavailable or difficult to identify. Advances in artificial intelligence (AI) have enabled increasingly accurate prediction of clinical outcomes from inexpensive, high-dimensional measurements, which creates an opportunity to use AI predictions themselves as surrogates. To this end, we develop a framework for estimating treatment effects from paired measurements obtained before and after treatment for each treated individual. A pretrained AI model is applied to the before and after measurements, and our estimator compares the resulting outcome predictions. We characterize the technical assumptions under which this within-person contrast identifies the average treatment effect on the treated, even when clinical outcomes are never observed for treated individuals. When these assumptions cannot be justified, we use prediction-powered inference to correct bias using a small number of observed clinical outcomes and obtain valid inference. Synthetic and real-world cardio-oncology experiments demonstrate the validity and accuracy of the approach.

Closest papers

Nearest neighbours by meaning across the whole index.

Causal multi-modal AI for personalized chemosensitivity prediction

cs.AI ·2026-09-11 ·Dhruva Biswas, Jeroen Berrevoets, Alec McClean, Linus Bao, Jungkyu Park +29 more
similarity 0.68
Abstract

Chemotherapy improves survival for some patients with breast cancer, but doctors cannot reliably predict who. Current guidelines rely on recurrence scores as a proxy for treatment benefit, which may contribute to the overprescription of chemotherapy. Here we present a causal multi-modal AI model that predicts personalized chemosensitivity using routinely collected pathology and clinical information. We developed our model on a multi-national dataset of 9,141 patients (twelve cohorts, nine countries) and evaluated it on another 1,994 patients (five cohorts, three countries). The model generated treatment-specific recurrence probabilities for each patient, with near-perfect calibration and strong prognostic discrimination across both 5- and 10-year follow-up horizons. Moreover, its chemotherapy benefit predictions demonstrated robust predictive performance, and out-performed existing recurrence-score-based tests. Compared to the standard of care, using the model to support personally tailored therapeutic decisions could reduce the number of patients receiving chemotherapy by 30% while achieving the same recurrence-free rate. Tumors predicted to be highly chemosensitive displayed concordant molecular and morphological programs of proliferation, cell cycle progression, and replication stress. The model's predictive capabilities transferred zero-shot to non-breast cancers, indicating our causal multi-modal AI approach may provide a universal strategy to predict treatment outcomes across cancer types.

0.52

SIRNET: Causal Adaptation of Pretrained Embeddings for Semiparametric Treatment-Effect Estimation Under Surrogacy

cs.LG stat.ME ·2026-09-29 ·Lei Shi, Qiuran Lyu
similarity 0.66
Abstract

Modern experiments increasingly produce rich post-treatment objects---such as text, images, and video---that may provide early surrogate signals for outcomes that are delayed, expensive, or observed only for a subset of participants. A pretrained encoder can turn such an object into a strong generic embedding, but the embedding is not trained for the estimation tasks required by a causal estimator and may emphasize information irrelevant to the causal target. We propose SIRNET, a Surrogate-Informed Representation adaptation framework for neural-NETwork-based causal estimation in the presence of unstructured post-treatment surrogates. Starting from pretrained surrogate embeddings, SIRNET learns a shared adapter jointly for outcome prediction, treatment propensity, and arm-specific surrogate marginalization, beyond the generic pretraining objective. The resulting covariate and surrogate representations provide a common interface for these nuisance tasks. The final treatment-effect estimate and confidence interval are obtained from cross-fitted orthogonal scores that attain the semiparametric efficiency bound under the stated nuisance-rate conditions. We also validate SIRNET's performance in synthetic and semisynthetic experiments, as well as the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) trial, using frozen pretrained brain-MRI embeddings as surrogates for a long-term outcome.

0.26

Rethinking How We Evaluate Methodological Progress in Health AI

cs.LG cs.AI ·2026-09-16 ·Florent Pollet, Matthew McDermott
similarity 0.64
Abstract

Methodological progress in artificial intelligence (AI) for electronic health records (EHRs) depends on our ability to determine which algorithms work better, and under which conditions. However, such progress is thought to be hindered by difficulties in reproducibility and in defining clinically meaningful evaluation tasks. We empirically study these barriers by re-implementing 12 historical and recent algorithms within a shared evaluation framework and evaluating them on two clinical datasets, MIMIC-IV and NWICU. We compare two complementary task families: expert-authored clinically meaningful tasks and generated tasks defined from randomly sampled event codes and prediction horizons. We ask whether relative algorithms comparisons transfer across task families and datasets, whether residual task heterogeneity contains useful methodological structure, and what a controlled comparison reveals about progress over the last decade. We find that aggregate pairwise comparisons transfer strongly across evaluation settings, including from randomly generated tasks to clinically meaningful tasks and across datasets. At the same time, clinically meaningful tasks exhibit greater task-method interaction, providing preliminary evidence that task properties can help explain when particular modeling choices are advantageous. Finally, newer algorithms do not consistently outperform earlier approaches: gradient-boosted trees remain highly competitive when paired with a modern, wide and sparse representation of the EHR. Together, these results suggest that useful methodological knowledge may require less task engineering than commonly assumed, while highlighting the importance of understanding the structured heterogeneity that remains across tasks and methods.

0.42

Weighted Spline-Expanded Networks with Distributional Balancing for Continuous Treatment Effects

cs.LG stat.ML ·2026-09-27 ·Shucheng Liu, Chan Park, Guanhua Chen
similarity 0.64
Abstract

Estimating causal effects with continuous treatments in observational studies is challenging due to confounding, model misspecification, and high-dimensional covariates. We propose the Weighted Spline-Expanded Network (WSENet), an end-to-end neural framework that addresses these challenges by combining covariate balancing, structured treatment embedding, and bias-corrected outcome estimation. WSENet first applies Distance Covariate Optimal Weights to induce distributional independence between covariates and treatment without relying on parametric models. It then learns the conditional outcome via a structured network that fuses outcome-relevant representations of covariates with a spline-expanded treatment input, enabling smooth and flexible modeling of the dose-response relationship. To mitigate residual bias, we introduce Weighted Targeted Regularization, a correction technique based on efficient influence functions that yields a doubly robust estimator. Extensive evaluations on semi-synthetic and real-world datasets, including high-dimensional genomic and environmental health data, demonstrate that WSENet consistently outperforms existing baselines in both accuracy and stability.

0.15

Auto-MD-bench: Evaluating Autoresearch Agents for Real-World Medical Tasks

cs.LG cs.AI ·2026-10-18 ·Shenqi Zhou, Qiran Zou, Wenhao Zhao, Zhenyu Liao, Dianbo Liu
benchmarkcode/data similarity 0.63
Abstract · 24 pages, 5 figures, 22 tables. Code: https://github.com/Edwin0080/Auto-MD-bench ; data: https://huggingface.co/datasets/Edwin0080/Auto-MD-b…

Autonomous agents are increasingly capable of developing machine learning (ML) models end to end. In medical practice, however, strong performance on the target metric does not fully characterize how good the models are in real-world use cases. For example, medical ML models should also provide well-calibrated risk estimates and remain robust across patient populations. Yet autonomous model development is typically guided by task objectives that emphasize simple predictive discrimination (e.g. AUROC). This raises a key question: are these objectives sufficient to guide agents toward models that meet the broader requirements of real-world medical use? In this study, we introduce Auto-MD-bench, a benchmark of 15 real-world medical tasks from 10 clinical datasets, spanning survival analysis, classification and sequential prediction, with external validation across cohorts, hospitals and time periods. We evaluate four agents: AIDE, AI Scientist v2, Codex, and Autoresearch. The strongest agents achieve competitive primary scores, yet their predicted risks are less calibrated than those of the simple baseline models, which could lead to severe medical accidents. Moreover, models with nearly identical primary scores can exhibit markedly different calibration, while performance varies substantially across population shifts. These findings show that primary task performance alone is insufficient to assess autonomous clinical modeling and multiple different metrics widely used in healthcare practice need to be taken into consideration.

0.29

Transcriptome-informed multi-modal AI for predicting neoadjuvant therapy response from breast cancer biopsies

cs.AI ·2026-10-02 ·Jungkyu Park, Dhruva Biswas, Joseph Cappadona, Cerise Tang, Ken G. Zeng +20 more
similarity 0.63
Abstract

Scarcity of labeled data limits development of deep learning biomarkers in oncology. We develop a two-stage AI model predicting pathological complete response (pCR) to neoadjuvant therapy in breast cancer. The first stage learns the transcriptome from histopathology using 8,742 patients across 32 cancer types, corroborated by pathologist review and spatial agreement with measured expression. This simplifies the second stage to predicting pCR from inferred expression and clinical variables. Developed using 1,080 patients (five cohorts) and evaluated in 1,412 patients (nine cohorts), the model achieves a pooled AUROC of 0.79 (95% CI, 0.73-0.85), discriminating responders within molecular subtypes. It outperforms histopathological biomarkers, remaining stable across intratumoral sampling and with minimal biopsy tissue. Ablations show transcriptome-wide inference improves discrimination over clinical variables alone or one-stage pathology models, and robustness by avoiding genomic assays' gene selection constraints. These results indicate that biologically informed compression may generalize to data-sparse applications in precision oncology.

0.06

CoMedBench: A Multi-Source Benchmark of Synthetic Medical Data Fidelity and Downstream Utility

cs.LG ·2026-08-13 ·Akanta Das, Farhad Al-Amin Dipto, Mrinmoy Sarkar Anto, David Rehkopf, Ayin Vala +1 more
benchmark similarity 0.63
Abstract

Access to clinical data is essential for developing reliable healthcare machine learning systems, but direct use of electronic health records is constrained by privacy regulation, institutional review, data-use agreements, and the risk of re-identification. Synthetic data promises a practical alternative: it can preserve useful statistical and clinical structure while reducing exposure of sensitive patient records. Prior studies often evaluate a single generator, one dataset, or a narrow downstream task, making it difficult to know when synthetic data can support model development and when it fails to preserve task-critical signal. We introduce CoMedBench, a reproducible benchmark that evaluates a family of generators under a common clinical-validity framework and one shared training and evaluation engine, spanning static tabular and temporal downstream tasks on established critical-care datasets. In total the benchmark spans 37 dataset-task pairs across two modalities consists of 20 static tabular and 17 temporal ICU time-series-drawn from seven public data sources: three intensive-care databases (MIMIC-III, MIMIC-IV, and eICU) together with the UCI Machine Learning Repository, the CDC BRFSS diabetes cohort (2015), NHANES (1999-2014), and the pycox survival datasets (GBSG and METABRIC). The benchmark evaluates both statistical fidelity and task utility by comparing models trained and tested across real and synthetic data. In these settings, synthetic training data preserves most of the downstream signal: on tabular tasks the reference generator CoMed-CTGAN retains a mean AUROC utility (the synthetic-to-real performance ratio) of 90.6%, rising to 97.3% for the strongest generator, CoMed-TVAE. Temporal ICU tasks are harder and more generator-sensitive: CoMed-CTGAN retains 81.6% (AUROC) and only 64.0% under the imbalance-sensitive AUPRC, whereas CoMed-TVAE still retains ~95% (AUROC).

0.04

Augmented Hypothesis Testing with Persona-Based LLM Simulations

cs.LG cs.AIstat.AP ·2026-09-21 ·Ziyad Benomar, Aymen Al Marjani, Paul Missault, Saab Mansour
similarity 0.63
Abstract · Work accepted at COLM Workshop on Agent Behavior

A/B testing requires large sample sizes, long timelines, and significant costs. When auxiliary predictions of experimental outcomes are available from machine learning models, uncertain prediction quality precludes replacing human experiments entirely, yet these predictions may still contain useful signal. We propose a principled framework for learning-augmented hypothesis testing that leverages predictions of unknown quality to reduce sample sizes while maintaining statistical validity. Predictions naturally vary in granularity, from coarse aggregate signals to fine-grained individual-level estimates, and our framework addresses both ends of this spectrum: (1) for population-level directional predictions, where only a binary signal on the treatment effect sign is available, we use an asymmetric test and prove consistency and robustness bounds within the learning-augmented algorithms paradigm; (2) for individual-level predictions, we introduce Generalized PPI++ (GPPI), extending Prediction-Powered Inference to handle nonlinear prediction errors through higher-dimensional transformations. Both methods benefit from accurate predictions while remaining robust to inaccurate or adversarial ones. We validate our framework using persona-based LLM simulations, where AI agents equipped with user personas predict individual behavior, as a natural prediction source spanning both granularity levels. Experiments on four real-world datasets demonstrate that our methods, combined with persona-based predictions, substantially reduce experimental costs while preserving rigorous statistical validity.

0.18